Education and Communication on the Topic of Osteonecrosis of the Jaw When Taking Bone‐Stabilizing Drugs

Abstract

ObjectivesThe aim of this study was to analyze the communication between doctors and patients who were taking bone‐stabilizing medication and in rare cases developed osteonecrosis of the jaw as a result.Material and MethodsA standardized questionnaire recorded deficits based on patient experiences. These data were used to develop solution strategies for improving doctor–patient communication and the benefit–risk assessment of medication use.ResultsMost patients were satisfied with the information provided by their doctor; however, one in three (29.8%) were not informed about possible side effects, and a quarter (24.6%) only found out about osteonecrosis of the jaw through their own research. Only half (45.7%) were asked about risk factors, and most information materials were rated poorly. The diagnosis took an average of 18.7 months, with many (47.8%) consulting a doctor only when they experienced pain. Quality of life was severely impaired, with daily pain, physical limitations, and negative effects on mental health. About a third (35.3%) reported that their quality of life had deteriorated significantly.ConclusionsFurther research into patient education is necessary. Web‐based information brochures, improved follow‐up care, and close cooperation with dentists are required. The use of a running sheet, such as the AGSMO running sheet, for individual risk assessment of osteonecrosis of the jaw is recommended. Patients undergoing treatment with bone‐stabilizing medication should be monitored closely. Education about osteonecrosis of the jaw must be continued, and the medical profession must be confronted with it.